Coya Therapeutics, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE8-KCoya Therapeutics, Inc.COYA5d

   Coya Therapeutics initiates OLE trial

   • Initiates open-label extension of Phase 2/3 ALSTARS Trial
   • OLE to begin November 2026
   • Phase 2 FTD trial delayed to 2027
2. ROUTINE8-KCoya Therapeutics, Inc.COYAOct 5

   Coya Therapeutics hits 120-patient enrollment in ALS trial

   • 120 patients enrolled in Phase 2/3 ALSTARS Trial
   • Topline data expected in early Q2 2027
   • Trial evaluates COYA 302 for ALS treatment
3. ROUTINE8-KCoya Therapeutics, Inc.COYASep 15

   Current report

4. NOTABLE10-QCoya Therapeutics, Inc.COYAAug 11

   Quarterly report

5. ROUTINE8-KCoya Therapeutics, Inc.COYAAug 11

   Current report

6. ROUTINE8-K/ACoya Therapeutics, Inc.COYAAug 7

   Current report (amended)

7. ROUTINESCHEDULE 13G/ACoya Therapeutics, Inc.COYAJul 27

   Ownership stake disclosure by Orin Hirschman (amended)

   Orin Hirschman, filed by

8. ROUTINE8-KCoya Therapeutics, Inc.COYAJun 25

   Current report

9. ROUTINEARSCoya Therapeutics, Inc.COYAMay 13

   Annual report to shareholders

10. ROUTINEDEFA14ACoya Therapeutics, Inc.COYAMay 13

    Additional proxy materials

11. ROUTINEDEF 14ACoya Therapeutics, Inc.COYAMay 13

    Proxy statement

12. ROUTINE8-KCoya Therapeutics, Inc.COYAMay 12

    Current report

13. ROUTINE424B5Coya Therapeutics, Inc.COYAMay 12

    Securities offering

14. NOTABLE10-QCoya Therapeutics, Inc.COYAMay 12

    Quarterly report

15. ROUTINE8-KCoya Therapeutics, Inc.COYAMay 12

    Current report

16. ROUTINE4Coya Therapeutics, Inc.COYAApr 9

    2 insider filings

    Mark H Pavao, insider filing for COYA

    Show all 2

    • 4Insider filing for COYAApr 9
    • 3New insider at COYAApr 9

    Mark H Pavao, reporting

17. ROUTINE8-KCoya Therapeutics, Inc.COYAApr 2

    Current report

18. ROUTINEEFFECTCoya Therapeutics, Inc.COYAMar 23

    Registration declared effective

19. ROUTINE424B3Coya Therapeutics, Inc.COYAMar 20

    Securities offering

20. ROUTINES-3Coya Therapeutics, Inc.COYAMar 16

    Securities offering

21. NOTABLE10-KCoya Therapeutics, Inc.COYAMar 16

    Annual report

22. ROUTINE8-KCoya Therapeutics, Inc.COYAMar 16

    Current report

23. ROUTINESCHEDULE 13GCoya Therapeutics, Inc.COYAMar 12

    Ownership stake disclosure by Dr. Reddy's Laboratories, Inc.

    Dr. Reddy's Laboratories, Inc., filed by

24. ROUTINESCHEDULE 13G/ACoya Therapeutics, Inc.COYAJan 30

    Ownership stake disclosure by VANGUARD GROUP INC (amended)

    VANGUARD GROUP INC, filed by

25. ROUTINE8-KCoya Therapeutics, Inc.COYAJan 30

    Current report

26. ROUTINESCHEDULE 13G/ACoya Therapeutics, Inc.COYAJan 28

    Ownership stake disclosure by Orin Hirschman (amended)

    Orin Hirschman, filed by

27. ROUTINE4Coya Therapeutics, Inc.COYAJan 26

    4 insider filings

    David S Snyder, insider filing for COYA

    Show all 4

    • 4Insider filing for COYAJan 26
    • 4Insider filing for COYAJan 26
    • 4Insider filing for COYAJan 26
    • 4Insider filing for COYAJan 26

    David S Snyder, reporting

28. ROUTINE8-KCoya Therapeutics, Inc.COYAJan 20

    Current report

29. ROUTINE8-KCoya Therapeutics, Inc.COYAJan 8

    Current report

30. ROUTINE4Coya Therapeutics, Inc.COYAJan 6

    5 insider filings

    Anabella Villalobos, insider filing for COYA

    Show all 5

    • 4Insider filing for COYAJan 6
    • 4Insider filing for COYAJan 6
    • 4Insider filing for COYAJan 6
    • 4Insider filing for COYAJan 6
    • 4Insider filing for COYAJan 6

    Anabella Villalobos, reporting

31. ROUTINE8-KCoya Therapeutics, Inc.COYADec 17, 2025

    Current report

32. NOTABLE10-QCoya Therapeutics, Inc.COYANov 12, 2025

    Quarterly report

33. ROUTINE8-KCoya Therapeutics, Inc.COYANov 12, 2025

    Current report

Older filings on EDGAR